Dana Walsh, PhD, is a Microbiome Analysis Scientist at Rebiotix Inc, a Ferring Company, where her primary role is the analysis and evaluation of complex microbiome data supporting the development of formulations under the Company’s MRT™ drug platform. Ferring, through Rebiotix, is revolutionizing the treatment of debilitating disease by harnessing the power of the human microbiome. The Company’s MRT platform drives the development of formulations which deliver live microbes as a means to treat disease.
Dr. Walsh’s career has consistently focused on the human microbiome in a variety of contexts. She received her PhD from the University of North Carolina in Chapel Hill, where she studied the impact of inhaled toxins on the airway microbiome in victims of burn and inhalation injury. She completed her postdoctoral fellowship at Mayo Clinic in Rochester, Minnesota (USA), where she investigated the role of the microbiome in cancers of the reproductive tract, including ovarian and endometrial cancer. Dr. Walsh continues her investigations into the microbiome in the industrial sector in support of a wide arena of therapeutic areas with a current emphasis on infectious diseases.
Disclosure: Rebiotix Inc. (Individual(s) Involved: Self): Employee